We use cookies on our website. Carry on browsing if you’re happy with this or find out more


Strategic partnership to enhance antibody drug discovery capabilities

Lifearc logo

Our strategic partnership agreement with LifeArc, a leading UK medical research charity, provides LifeArc with access to Kymab's advanced suite of next generation antibody discovery technologies, building on the charity's success to date in antibody generation and selection.

These technologies include Darwin, one of Kymab's new transgenic platforms that replaces the original transgenic platform, combined with its human antibody screening platform which together can quickly deliver candidate therapeutics with the most desirable drug-like properties. The IntelliSelect® technology platforms are designed to rapidly generate in vivo mature, fully human monoclonal antibodies.

Our unique platforms can deliver the finest novel therapeutic antibodies

Learn more